Shares of Kythera Biopharmaceuticals Inc. skyrocketed 25 percent on Tuesday after the Calabasas biotech announced positive clinical trial results for its lead pipeline drug that reduces double chins....

Join our Membership to get the full story.


Are you a current Member? Sign In